DIWALI SPECIAL

25% OFF + 1-Yr NT Prime FREE !

Use
00h : 00m : 00s
Claim Offer →
logo
Market statusData NSENot investment advice
SURAKSHA DIAGNOSTIC

SURAKSHA DIAGNOSTIC Latest Share Price (SURAKSHA)

₹341.70
0.70+0.21%
Overall Score68/100
Day range334
₹341.70
355
52-week224
₹341.70
384
Above low+52.5%
Below high11.0%
Range position74%
Open341.90
Prev Close341.00
Bid341.68100
Ask341.72100

TODAY IN ONE LINE

SURAKSHA is little changed at ₹341.70 on above-average volume (2.7x avg) — a quiet consolidation day.

With a market cap of ₹1,800.69 Cr., it trades at a P/E of 43.06. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.

Volume125.6K−16%vs 20D avg
Price Band20
Lower Band231.2
Upper Band346.7
Tick Size0.05
Daily Volatility2.16%
Annualised Vol41.27%
Market Cap₹1,800.69 Cr.
Promoter49.1%
Face Value₹2
Fwd P/E30.29
PEG3.04
EV/EBITDA8.98
P/S4.42
ROA8.7%
Beta0.72
Div Payout—
THE STOCK SCORE
Overall Score68/100
Updated 07 Sept

How good is this company?

Overall performance across 5 key dimensions.

Each card tappable → shows formula + inputs
FLAGS & NEWS

SURAKSHA DIAGNOSTIC flags & news 

Key strengths, potential risks, and recent updates.

✅ 5 green flags🚩 2 red flags

Green Flags

  • ●High Capital EfficiencyROCE of 15.2% indicating pricing power
  • ●Healthy Operating MarginsOPM is structurally strong at 19.8%
  • ●Virtually Debt-FreeVery low Debt-to-Equity of 0.01x
  • ●Positive Free Cash FlowFCF has been positive for 3 consecutive years
  • ●Zero Pledge RiskNo recent active promoter pledging found

Red Flags

  • ●Earnings DeclineEPS (TTM) has contracted by 5.4% YoY
  • ●Rising Receivables vs SalesReceivables grew 72.4% outpacing sales growth of 15.3%

Latest SURAKSHA DIAGNOSTIC News

THE CHANGELOG

What changed recently?

Recent events, corporate actions, and announcements.

13 NOV 2026
corporate
Analysts/Institutional Investor Meet/Con. Call Updates - Suraksha Diagnostic Limited has informed the Exchange about Link of Recording
View PDF
12 NOV 2026
corporate
Investor Presentation - Suraksha Diagnostic Limited has informed the Exchange about Investor Presentation
View PDF
12 NOV 2026
corporate
Press Release (Revised) - Suraksha Diagnostic Limited has informed the Exchange regarding a revised press release dated Novemb...
View PDF
12 NOV 2026
corporate
Updates - Suraksha Diagnostic Limited has informed the Exchange regarding 'Clarification regarding Non-Publica...
View PDF
12 NOV 2026
corporate
Investor Presentation - Suraksha Diagnostic Limited has informed the Exchange about Investor Presentation
View PDF
11 NOV 2026
corporate
Updates - Suraksha Diagnostic Limited has informed the Exchange regarding 'Corrigendum to the Press Release -I...
View PDF
11 NOV 2026
corporate
Copy of Newspaper Publication - Suraksha Diagnostic Limited has informed the Exchange about Copy of Newspaper Publication
View PDF
10 NOV 2026
corporate
Press Release - Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated November 10, 2...
View PDF
10 NOV 2026
corporate
Outcome of Board Meeting - Outcome of Board Meeting held today i.e. 10th November 2026
View PDF
🔒Prime: full history + alerts on this stock
Valuation

SURAKSHA DIAGNOSTIC valuation: P/E, P/B and sector benchmarks.

Twelve years of multiples investors have paid for SURAKSHA DIAGNOSTIC, framed against the sector median so the premium or discount is obvious at a glance.

SURAKSHA DIAGNOSTIC trades at a P/E of 43.06× and P/B of 6.52×.

Key MetricsMarket + reported · 13 Nov 2026Consolidated

Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.

Valuation

Valuation

Market Cap
₹1,800.69 Cr.
P/E Ratio
43.06
P/B Ratio
6.52
EPS
₹2.5
Profitability

Profitability

ROE
13.64%
ROCE
15.19%
Net Margin
10.37%
Op Margin
19.81%
Growth

Growth

EPS YoY
-5.4%
Revenue YoY
31.2%
Qtr Sales
—
Qtr Profit
—
Financial Health

Financial Health

Debt / Equity
0.01
Book Value
₹46.75
Div Yield
0.29%
Promoter Holding
49.1%
Technicals

SURAKSHA DIAGNOSTIC technical analysis: indicators, pivots and CPR.

Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for SURAKSHA DIAGNOSTIC — derived from the latest tape, not yesterday's close.

SURAKSHA DIAGNOSTIC last traded at ₹341.7 with an intraday range of ₹334.35–₹355 — latest indicator, pivot and CPR signals below.

Last updated: 16 November 2026, 4:08 pm IST

Pivot points

Standard pivot — most widely referenced.

Pivot levels · Classic

Last: ₹341.70
LevelPrice (₹)Distance% Δ
R4394.32+52.62+15.40%
R3373.67+31.97+9.36%
R2364.33+22.63+6.62%
R1353.02+11.32+3.31%
PIVOT343.681.980.58%
CURRENT341.70——
S1332.37-9.33-2.73%
S2323.03-18.67-5.46%
S3311.72-29.98-8.77%
S4291.07-50.63-14.82%
CPR Levels
Support
Resistance
S4
S3
S2
S1
| CPR |
BC: 342.69P: 343.68TC: 344.68
R1
R2
R3
R4
indicator
LTP: 341.70
PDH: 360.00
PDL: 340.10
● Market Sentiment

SURAKSHA is trading Below CPR, indicating Bearishness

● CPR Width

CPR is Wider, suggesting unlikely for trending moves

● Opening Range

Day's range: ₹334.35–₹353

● Price Position

Trading Inside opening range

Financials

SURAKSHA DIAGNOSTIC financials: P&L, balance sheet, cash flow, ratios.

Reported annual and quarterly results for SURAKSHA DIAGNOSTIC — consolidated or standalone — with margins, YoY growth and key ratios inline.

SURAKSHA DIAGNOSTIC reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹1,800.69 Cr. and reported EPS of ₹2.50.

iTap any row for a plain-English meaning▲▼Change vs a year ago — green means the move is healthy for that line, red means it isn’tDerivedCalculated by us, not reported directly
Mobile view
Latest vs previous year
MetricMar 2026May 2026
Revenue from Operations310
310
▲ 0.0%
Sales Growth YoY %Derived23.14%
—
Other Income3
3
▲ 0.0%
Total Income314
314
▲ 0.0%
36
36
▲ 0.0%
Gross ProfitDerived274
274
▲ 0.0%
Gross Margin %Derived88.25%
88.25%
179
179
▲ 0.0%
EBITDA (Operating Profit)Derived95
95
▲ 0.0%
OPM %Derived30.73%
30.73%
54
54
▲ 0.0%
Profit Before Tax (PBT)45
45
▲ 0.0%
13
13
▲ 0.0%
Effective Tax %Derived29.52%
29.52%
Total Profit for Period31
31
▲ 0.0%
Less: Non-controlling Interests-1
-1
▲ 0.0%
Net Profit (Owner's PAT)Derived32
32
▲ 0.0%
Net Profit Margin %Derived10.37%
10.37%
PAT Growth YoY %Derived1.14%
—
Earnings Per Share (EPS ₹)6.18
6.18
▲ 0.0%
Diluted Shares Outstanding (Cr)5
5
▲ 0.0%
Other Comprehensive Income (Net of Tax)1
1
▲ 0.0%
Total Expenses (incl. D&A & Interest)269
269
▲ 0.0%
Material Cost % of RevenueDerived11.75%
11.75%
Employee Cost % of RevenueDerived17.16%
17.16%
Other Cost % of RevenueDerived40.36%
40.36%
Interest Coverage (x)Derived4.30x
4.30x
Sales CAGR · 3Y
+7.2%
PAT CAGR · 3Y
+0.4%
all values in ₹ Cr unless marked % / x / ₹ · fiscal-period end shown · reported figures via Stockezee financials API · annual results may be audited; quarterly results may be unaudited or limited-review
Segment Analysis

SURAKSHA DIAGNOSTIC segment analysis : revenue and profit mix.

Disclosed business segments at SURAKSHA DIAGNOSTIC with their share of revenue and profit, switchable between consolidated and standalone reporting.

SURAKSHA DIAGNOSTIC discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.

Segment-wise Financial Analysis

Thesis

The Bull, Bear, and Flip case for SURAKSHA DIAGNOSTIC.

Our AI distills the core fundamental drivers supporting SURAKSHA DIAGNOSTIC, the risks that threaten it, and the quantitative conditions that could weaken the thesis.

bull case

What you're getting.

No strengths or opportunities on record.

bear case

Key Risks.

No weaknesses or threats on record.

flip conditions

Flip Conditions.

  • Valuation risk. a P/E above 56 would leave less room for earnings disappointment.

  • Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.

  • Return-quality risk. ROE below 9% would indicate weaker capital compounding.

  • Income thesis breaks if the dividend is cut or yield falls below 0.14%.

Shareholding

SURAKSHA DIAGNOSTIC shareholding pattern: promoters, FII, DII and public.

Quarter-on-quarter ownership shifts in SURAKSHA DIAGNOSTIC — who is buying, who is exiting, and which institutions hold the largest positions.

Shareholding Pattern

Annual • Sep 2026

DII21.56%↓1.67%
Promoters49.10%
FII13.97%↑0.50%
Public15.37%↑1.16%

Ownership Distribution

Domestic Institutions
21.56%
Promoters
49.10%
Foreign Institutions
13.97%
Retail & Public
15.37%

Category Trends

Foreign Institutions Breakdown
Total Holding: 13.97%
Net Change: +0.50%
Category Total13.97%
Total Holding13.97%
Net Change+0.50%
Not Fully Disclosed

⚠️Partial Disclosure Notice

Individual institutions below total 12.88%, but category aggregate is 13.97%. Some institutions may not be disclosed by the company as per regulatory requirements.

Institution Name
Trend (Last 6)
Holding %
QoQ Change
YoY ChangePeriod
Orbimed Asia II Mauritius Limited
12.88%
0.00%
0.00%
Sep 2026
Peers

SURAKSHA DIAGNOSTIC peer comparison — same-sector benchmarks.

Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — SURAKSHA DIAGNOSTIC is highlighted for quick read-across.

Quick Compare

Largest by Market Cap
DR. LAL PATH LABS
₹33,301.21 Cr
Best Profit Growth
KRSNAA DIAGNOSTICS
48.55 %
Highest Dividend Yield
THYROCARE TECH
1.41 %
09 · Chart Patterns

SURAKSHA DIAGNOSTIC chart patterns: breakouts, tops and bottoms.

Auto-detected classical chart patterns for SURAKSHA DIAGNOSTIC — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.

Delivery Conviction

SURAKSHA DIAGNOSTIC delivery volume — last 20 sessions of conviction.

Daily traded volume and delivery percentage for SURAKSHA DIAGNOSTIC over 20 sessions — the gap between intraday flipping and genuine accumulation.

Latest session delivery in SURAKSHA DIAGNOSTIC stood at 31.6% of traded volume, against a 20-day average of 48.4%.

Avg Delivery (20D)48.4%-16.9 ppt latest vs avg
Highest Delivery74%on 06 Nov
Avg Volume (20D)1.50 L20-day run-rate
Conviction Trend↓ Weakening-16.9 ppt latest read
Volume & Delivery · last 20 sessions
Exchange Filings & Investor Updates

SURAKSHA DIAGNOSTIC announcements: results, concalls, ratings, M&A.

Filings SURAKSHA DIAGNOSTIC sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.

SURAKSHA DIAGNOSTIC files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 97 documents below.

  1. 13 Nov 2026Analysts/Institutional Investor Meet/Con. Call UpdatesView PDF

    Analysts/Institutional Investor Meet/Con. Call Updates

    Suraksha Diagnostic Limited has informed the Exchange about Link of Recording

  2. 12 Nov 2026Investor PresentationView PDF

    Investor Presentation

    Suraksha Diagnostic Limited has informed the Exchange about Investor Presentation

  3. 12 Nov 2026Press Release (Revised)View PDF

    Press Release (Revised)

    Suraksha Diagnostic Limited has informed the Exchange regarding a revised press release dated November 10, 2026, titled "Corrigendum to the Press…

  4. 12 Nov 2026UpdatesView PDF

    Updates

    Suraksha Diagnostic Limited has informed the Exchange regarding 'Clarification regarding Non-Publication of Newspaper Advertisement under Regulation…

  5. 11 Nov 2026UpdatesView PDF

    Updates

    Suraksha Diagnostic Limited has informed the Exchange regarding 'Corrigendum to the Press Release -Interview published in The Times of India dated…

Corporate Actions

SURAKSHA DIAGNOSTIC dividend history, splits and bonus issues.

Every dividend, stock split and bonus issue SURAKSHA DIAGNOSTIC has declared, sequenced by announce and record date.

SURAKSHA DIAGNOSTIC corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.

Insider Activity

SURAKSHA DIAGNOSTIC insider trading: promoter and management activity.

Promoter, director and designated-employee transactions in SURAKSHA DIAGNOSTIC as reported to SEBI — buying and selling signals from the people who know the business best.

SURAKSHA DIAGNOSTIC insider activity below tracks 1 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).

InsiderCategoryTxn DateActionQuantityValue (₹)Price
Dr. Somnath ChatterjeeInsider13 Jun 2025buy+7.6 K₹24.85 L₹327.41
About the Company

About SURAKSHA DIAGNOSTIC: business, sector, key facts.

What SURAKSHA DIAGNOSTIC does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.

SURAKSHA DIAGNOSTIC operates in the Healthcare Service Provider industry under the Healthcare sector, listed as NSE: SURAKSHA, BSE: 544293.

SURAKSHA
Healthcare

SURAKSHA DIAGNOSTIC

NSE · SURAKSHA·BSE · 544293·www.surakshanet.com

Suraksha Diagnostic Limited is a prominent player in India's diagnostic healthcare industry, operating a network of diagnostic centers throughout the country. The company's core business revolves around providing a comprehensive suite of diagnostic testing services to patients and healthcare professionals. This wide-ranging portfolio contributes to their significant market presence and caters to a diverse client base.

A significant portion of Suraksha's revenue stems from its pathology testing services. This encompasses a broad spectrum of laboratory analyses, allowing for the detection and diagnosis of various medical conditions. The precise nature and extent of these pathology tests are not detailed in the provided information, but the breadth of services offered is clearly a key component of their business model.

Further enhancing its diagnostic capabilities, Suraksha offers a comprehensive range of radiology services. This includes advanced imaging techniques such as Magnetic Resonance Imaging (MRI), Computed Tomography (CT) scans, and Dual-Energy X-ray Absorptiometry (DEXA) scans. These technologies provide detailed internal images of the body, assisting in the diagnosis and monitoring of a variety of health issues. Their radiology offerings also extend to interventional ultrasonography, CT-guided biopsies, and standard X-ray imaging, illustrating a dedication to comprehensive and technologically advanced diagnostic practices.

In addition to its core diagnostic testing services, Suraksha also provides medical consultation services. While the specifics of these services are not detailed, the inclusion of this element suggests an integrated approach to patient care, potentially offering a more holistic and convenient experience by combining diagnostic testing with preliminary medical advice. This could involve consultations with physicians or other healthcare professionals associated with the company.

Established in 1992 and headquartered in Kolkata, India, Suraksha Diagnostic Limited has a long history of serving the healthcare needs of the Indian population. Its continued growth and expansion within the diagnostic services sector demonstrates its success in meeting the demand for accurate and timely diagnostic information.

company facts
Employees—
SectorHealthcare
HeadquartersKolkata, India
Market Cap₹1,800.69 Cr.
Listed OnNSE
leadership14 on record
Dr. Somnath Chatterjee
Joint Managing Director, Executive Director
Dr. Somnath Chatterjee
Executive Chairman & Joint MD
Mr. Arun Sadhanandham
Nominee Director
Mr. Balgopal Jhunjhunwala
Regional Business Head
Mr. Dinesh Gupta
Chief Financial Officer
Mr. Karan Verma
Director (Promoter)
Mr. Niren Kaul
Chief Sales Operations
Mr. Ravindra K. S.
Group Chief Financial Officer
Ms. Mamta Jain
Compliance Officer, Company Secretary
Ms. Mamta Jain
Company Secretary & Compliance Officer
Ms. Ritu Mittal
Chief Executive Officer, Joint Managing Director, Executive Director
Ms. Ritu Mittal
Joint MD, CEO & Executive Director
§ ∞ · Plainly Answered

Questions investors ask about SURAKSHA DIAGNOSTIC (SURAKSHA).

Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.

01What is the current share price of SURAKSHA DIAGNOSTIC (SURAKSHA)?

The current share price of SURAKSHA DIAGNOSTIC (SURAKSHA) is ₹341.70. Today, the stock has gained by ₹0.70 (0.21%), trading in a range of ₹334.35 to ₹355.00. The stock opened at ₹341.90 with a trading volume of 1,25,593 shares.

02Is SURAKSHA DIAGNOSTIC stock a good investment for long-term?

SURAKSHA DIAGNOSTIC can be considered for long-term investment based on several factors. The company has a market capitalization of ₹1,800.69 Cr., P/E ratio of 43.06, ROE of 13.64%, and ROCE of 15.19%. The dividend yield stands at 0.29%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.

03What is the 52-week high and low price of SURAKSHA DIAGNOSTIC stock?

The 52-week high price of SURAKSHA DIAGNOSTIC (SURAKSHA) is ₹384.00, while the 52-week low is ₹224.10. Currently trading at ₹341.70, the stock is 52.48% above its 52-week low and 11.02% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.

04Should I buy SURAKSHA DIAGNOSTIC stock at the current price?

Whether to buy SURAKSHA DIAGNOSTIC stock at ₹341.70 depends on multiple factors. The stock is currently trading with a P/E ratio of 43.06 and P/B ratio of 6.52. Today's performance shows a gain of 0.21%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.

05What is the dividend yield of SURAKSHA DIAGNOSTIC and when is the next dividend?

SURAKSHA DIAGNOSTIC offers a dividend yield of 0.29%, which means for every ₹100 invested at the current price of ₹341.70, you can expect to receive approximately ₹0.29 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.

06What are the key financial ratios and metrics of SURAKSHA DIAGNOSTIC?

SURAKSHA DIAGNOSTIC's key financial metrics include: P/E Ratio: 43.06, P/B Ratio: 6.52, ROE: 13.64%, ROCE: 15.19%, Dividend Yield: 0.29%, EPS: ₹2.50, Book Value: ₹46.75, and Debt-to-Equity: 0.01. The company's market cap stands at ₹1,800.69 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.

07How is SURAKSHA DIAGNOSTIC stock performing today in the market?

SURAKSHA DIAGNOSTIC stock opened at ₹341.90 and is currently trading at ₹341.70, showing a gain of ₹0.70 (0.21%). The intraday high is ₹355.00 and low is ₹334.35. The trading volume stands at 1,25,593 shares, indicating moderate market participation today.

08What is the P/E ratio of SURAKSHA DIAGNOSTIC and what does it indicate?

SURAKSHA DIAGNOSTIC has a Price-to-Earnings (P/E) ratio of 43.06, which means investors are willing to pay 43.06 for every ₹1 of earnings. With an EPS of ₹2.50, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.

Disclaimer

The data, ratios and commentary about SURAKSHA DIAGNOSTIC (SURAKSHA) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.